Author	Year	Patient no	Liver disease	Patient age (years, median/mean)	Validation	Diagnostic tool	Fibrosis grade	AUC	Optimal cutoff	Time from tool to biopsy	Link	Comments
Lee	2013	128	Autoimmune (20), viral (16), cholestasis (16), PSC (9), fatty liver (9)	age group data: 0-2 (22%), 3-6 (13%), 7-11 (19), 12-17 (33)	METAVIR	VCTE	F3, F4	0.83	8.6 kPa	< 1 year	https://pdf.sciencedirectassets.com/272521/1-s2.0-S0022347613X00101/1-s2.0-S002234761300509X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEKn%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIAbQLrCg5FK4AD0XfW4Ln3VZ1xnFjlKcY0lvPblUHTEAiEAr6Mrx8pLIWRTSFbbvdnqQO08DAnGIlnUHy6i65Uk1LMqgwQIwv%2F%2F%2F%2F%2F%2F%2F%2F%2FARAEGgwwNTkwMDM1NDY4NjUiDIhKP8OmXWsa90xMBCrXA5kVOaA1wFw0oMlw7yqyxCkarCxlfyetR4ZJdX0r1DNZWDgPFOKNtUQES3xzCCSHnWA8i%2BF7TOrlWhqk2Dt6qDRTrNXXnOeoPUuJ%2B5qioSZgYF2yLyMWaKTcp8IHVkcM4aFbuuTWLr0BjxsKLJ1OjMes4UDGjHleLKVmIwFzZmk27pMXsZJVWLHWvGWECHW1U8itr%2Bz4fjw2nhXc5XwDCXetvYdOSdrGSfwytlyPwozOWVopSjdlyRT4taLmU4mxOo%2FWTlyiL6XHKo5XMDX8%2FwVvH18iS9PWmODa4B0W%2Fogrx7wk38Qv7971uIETYLleYCuAjm2rNTZXgmpVjvZFKU9C%2BbIQe0%2Fx6ErR84PdiFimr1UTgCO8ZIPxdlCQKs%2BhurtqeNyiwWFlG5oR%2FdIr2YHKwqTGyM8IAxVZeg4a0kYExjaMgSiKAttKyzQy26P3Bw%2B190kiam5f4l2VbXusXv%2BYWJ9Ronz%2B2Kclhsj%2BqcltaSOcmtdxbB%2Fa%2B1gRDgNYnqZqG7u1JYwqMhNqugnilnKIYuYc9icQ4TAWOPqHdPQn1pWc7Gha3Z8nB5ZVi0YJLk42MENnB247l%2FCaKGjdT%2FrArQ0Qdi5TtRQavJqesQrc2delF8w8DDcwJaPBjqlAcHpMtGOkzwkuvCi476fFxO7P%2B9idhFPFYmnzXLR%2Fz%2FcSK3MpQj3%2FobvcgB1QQ6%2B7%2BR2R2Qi1u2dv2H5D4s5zlSmfJzAg5KCNeU2ko449hSttAxFiU0S1brkq7Wldq1VcQw1%2FnJ93lUvlLGvhKWR1OlaOT44FuI40TJZ78vzJ8xlnC7iKuRttyGwlvrlkl7gMM9IuGED4eSycUizIGK4N3NnZgZA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220117T175302Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYZB4D5D5T%2F20220117%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=4cba5475ebf4db925498c2d2254092e1833dc293	
						HA	F3, F4	0.72	43 ng/mL			
						YKL-40	F3, F4	0.52	26.2 ng/mL			
						APRI	F3, F4	0.66	1.45			
						AST/ALT	F3, F4	0.64	0.84			
						AST/GGT	F3, F4	0.45	0.49			
Fitzpatrick	2013	101	Fatty liver (37), autoimmune (27), viral (8), Wilson (5)	13.6 (R 6-18)	METAVIR	VCTE	≥F1	0.81	6.1 kPa	< 1 month	https://pubmed.ncbi.nlm.nih.gov/22922372/	
						VCTE	≥F2	0.78	6.9 kPa			
						VCTE	≥F3	0.79	7.5 kPa			
						VCTE	F4	0.96	14.1 kPa			
Lewindon	2019	27	Cystic fibrosis	9.0 ± 0.4	METAVIR	VCTE	≥F3	0.89	8.7 kPa	N/A	https://pdf.sciencedirectassets.com/273402/1-s2.0-S1542356518X0024X/1-s2.0-S1542356519302794/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEK%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIQCl0mpv15WFnEkJSdm%2Bo6oVUBu36v9TePIIBx6Bne41zwIgM%2Ba%2FSWGRxX6Y3jAamXwY0ZebAUKF9Kb3w2QCv4sPsIIqgwQIyP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAEGgwwNTkwMDM1NDY4NjUiDPhnKQLzZC4NqqWj8irXAwCJc6P3rcZ%2FSWK8ID1s%2B9dabfsG1kvv9xQM37sQ7Gj2jF7tfo1hw1rRwXVhiLwOEzwzrPyNEq%2BD2NZdqGgE5OEqX%2Ft6yEf6LDkG9ohPBsxsGvzCo92EOrpitoTfpJFL8VPdxPfArj7G%2BuGYTiYU033Pz8smMFsarHgF%2FJECqSXbAfMTOlCs6IAUrlxZpyD761NISXmgwVVThN7xQZ1BigsEoEXZ3T3mJ%2BKUIHuymwj8Ku6e%2B%2BWd6sgU6Jy3Ufrjqip2ET%2FZTYJW0jLHvtrXk7V3frDnG4OhsxDYoHuFIF10%2BQZ%2BRXbMGuOZU3NeLWK16jxMgQjwdD0tWIMHLlxaLik05fHFzwyDzpTgY%2BmG4etVM8KU0BWm%2FPHctHN0HIjitZ9qA16uDIahMARKMMmjS0jYc3LmSxIplprSe%2B2ER7AEE5d8Bfa%2BT%2FJjXhU5tIUMUmxfpnpDz%2FjQr5ediuxioycU4nucRfidKmmvXZ2%2BECJX%2BL%2BJp2tKWE9zyUVGPNOZJLO2O%2BeKmMPQPS5a%2BNxis%2F%2Fz%2BAaVvx7%2FJcoaQciLgtX%2BWztiu5hAQJAV4wyLW8XNlgUHT%2FcbX8u%2FsO8gRsNZVJ97OA6uFIE3bh3OoiBidbbdU5PnCbIWMDDe35ePBjqlAqlzL%2B2bzry1Vr6N46upTKGv7lINR6pqEkMFKXoVJ6gFhsatJqgekNeS61xP592vMsAkso7rz1VaBPgphv3vLoLEi4PyP0dtuX9ryvOprX5d%2Fu41loxWdUReaL8u1mZulbKvFDxZW%2FFBu1VEz3P78dSOCopZbVc0heK8RYMaMq8QYbRRQ0UTK6tfn%2Bwuq%2FFk1kJCycVFuDfFpYU2PRP%2Fzjn51kXegOQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220117T233659Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY4NU5IQMD%2F20220117%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-	
Leung	2015	51	Cystic fibrosis	10.9 (IQR 7.5, 13.6)	METAVIR	APRI	≥F3	0.81	0.462		https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.28016	
						FIB-4	≥F3	0.7	n/a			
Pereira	2004	36	Cystic fibrosis	11.2±0.7	Scheuer	TIMP-1	Stage 2-4	0.725	300 ng/ml	N/A	https://pdf.sciencedirectassets.com/272181/1-s2.0-S0168827800X01626/1-s2.0-S0168827804003253/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEMP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIQChDdC2UjeWwmjORYwQmPqAVk2WWsC85UDt1RwmUFVWCAIgMXrDCoKXV2ogzKlwdzslBpTxz9DaE6KXYuGy5O10Uq0QgwQI2%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAEGgwwNTkwMDM1NDY4NjUiDKf778L0ffsQthyj5irXA61LtfIJiP75hXQaba7vbu9PfVaUWtpj8OpRsal3zKy2%2BWsF2VRq8X37sVjxp%2F5Eg1VoJoV2hPB9Chv4Dypw%2Fx584tFzgO04IdoQrYYK7Twv3vovH3crmgD0c0s7TuKnaZrw40hWIO9CYFXPrFBhbOYylvQFPDzJiDdxAzIP8%2B%2BVn3Hyhv%2Fwqo8ARdmtuOI5P%2F%2Bn9xN8junmwJffI00JDmP%2F%2B9fZGsoQbgMY8oHejMTV1oNfFL5VININ2Q8buHdr6pTu2MxzPs2pz7oDOOQoj90i48zTKZRqTpszLSTslDgtrsFjXRPHdzEgF8feocZGNvopru2JrRVKxejC9iq7pSWX3PlLWERAYDfXAtcHZbMvHnUJ0KChgQb6n2X98yP%2BS9c7kk7J4W%2F57BmKKeiC%2FHo0EZwe8ZZNwrCOC5%2FI3sFPHhWLkXYF0pKIzdygrSsbjgEwOlHLgo94eNyr%2BmFKJebpYN%2BqbkZQiE3UwpDWjP8%2F1aRpn1njlF3idSQ6bagK4OovTcyCaQ56Xc84fXRHrP6Stw4L4i%2F7TnmHHRlgi4tznc9H3yb15n0lHsvn7sI2A8xep3Q6Ti4EugxlCxpOdCJ8tRPJ7uu%2Bj%2BwARFntvl1SGMCw84RgDD9IZyPBjqlAVW3Ukq%2F%2FuuTcIMdzhXJEq1mqKmtW7qwnJEYbYQ%2B9CispVCvfsIrWaH%2FRPXLIj0g6zCPjQAqlzCgUQbd6HChoGuBf2OGlbabcZMFs0VZ1lo3tFCP145B6GJeGIj0IZRzwAsqZurL%2BaWDEoLIKDDSxyGd6cOJ5N45Zfb0r%2FGLiLcfJl1Nytq3wQldF5els9eJbHASGNKcKckRsDzdWxDYNzy%2BsCmjvg%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220118T191721Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY3Y3W3MXK%2F20220118%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=a97aded6827f2069c8b5fe33dbfa2d03ecc46c568	
						COL-4	correlation analysis	no correlation	n/a			
						MMP-2	correlation analysis	no correlation	n/a			

						HA	correlation analysis	no correlation	n/a			
						PH	Stage 2-4	0.814	59 ng/ml			
						Equation TIMP-1 + PH	Stage 2-4	0.852	0.5			
Mercedes	2020	16	Chronic viral hepatitis (HBV, HCV)	12.6 (R 3.4, 17.9)	METAVIR	SWE	Wilcoxon: F0-1 vs F2-3	ns	n/a	≤ 1 week	https://journals.sagepub.com/doi/pdf/10.1177/2333794X20938931	Previous studies showed reproducibility of SWE, but not this one.
						TIMP-1	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						FIB-4	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						PH	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						HA	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						COL-4	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						IL-8	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						PDGF-BB	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						sICAM	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						LH	Wilcoxon: F0-1 vs F2-3	ns	n/a			
						APRI	≥F2	0.875	n/a			
						MCP-1	≥F2	0.813	n/a			
						sFas	≥F2	0.823	n/a			
						Equation (APRI × MCP-1)/sFas	≥F2	0.92	49.8			
Galal	2020	46	Chronic hepatitis C	15.52 ± 2.71	METAVIR	SWE	≥F2	n/a	7.6 kPa	< 6 months	https://pdf.sciencedirectassets.com/278545/1-s2.0-S1687197920X00050/1-s2.0-S1687197920300848/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjENv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIQDDDRUM9pdyDC3fbgIFz%2BLII%2FAhpVIAT12%2Falpiuprz%2FQIgLhL9ZnSvQCj%2FdHWQZKVgzicMENEHIExUcOO580Pgrvoqgw9I9P%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAEGgwwNTkwMDM1NDY4NjUiDABAiGs13zFx%2BPjrSCrXA%2FoLwv4LamT7yAQaf2akYzfGzd3VWPj32SIj3H2usSefgEfqGAwZ8qRKpU8d0e3bmRMNxkUNWWP2pehfePE1ciuzXahUnCFypdI3TCnlyrYDX2QY1pS3hePiQAk0pvJpyXuRKuYKSNjDaq1kp624CfrbI6fNU6kOph5qbp43qVjSS3FZ4ICOeIx7F4bO80NvVI3S0K2G6gjslvD%2FERsSFXksMVOuOhe3XkZ1U8FBc822F6HNaAj6xlL8auqUzhvXNiH7vDPXSEU4oIWwk8YbXmrWEkWEPNK%2B67dvlksy2P0ypoEXU%2Bi4ONPwC%2BPs%2BjSY5CIEAZ08duiSNJDefrj1MojxN%2BY0zwwsPY4XDHddM9IAcCvid8K5MYuYoHQySYCk2FYyuxIXz7b1Ws%2BgrJVWw5JRAx19k9W3cIiCCFE7h0WS8%2B8IyMN41YWHGp5wF%2FSG9aNWDbA%2FAxoJNTJRFiFV7mj9EAiAPLAFTDHZnR1Ccu%2F8dRtSDuwIlvfplq%2F%2F1Pr3DSJa%2BZCzA7LKqjZ6nIn6MXPnVzuGmN%2FDKrnrLoACZRHEKCtivx3OTZX1K42PzhyVagyvIJTFXvOZd1AYiJCs1aal6p%2FxzESaYmt0teepTP5TvLwiYpMRCxTCMv6GPBjqlAcWopB5zz9GTAGeC0HxiTuC9ac4qS8FjGWbdO4rS1kFgeFTL0Qelb5MxJJasCvPCPWwZTc4eygB90NJUMTeS0Zmq%2B4XRQ0A0mFovAjv2j%2Fk%2BSSYbcO4pTgMouUxjkua8r3Op%2BNrS48VBZ%2BINaXUieygql7SHLz15ahWOGYeLf09W2PkRMcHGY9FO8SdbKurSOtBjCGGJOhFycLbddgSzaBA2Zk6niA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220119T190416Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY5F4JINWV%2F20220119%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=c0b855c4bfd4d9a86b63bf2e58ea1142cc728c9e	
						APRI	≥F2	0.679	0.619			
Ledinghen	2007	33	Biliary atresia (27), AIH (15), Wilson (9), viral (6), CHF (6)	9.5±6.8	METAVIR	VCTE	F4	0.88	n/a	≤ 1 week	https://journals.lww.com/jpgn/Fulltext/2007/10000/Cow_s_Milk_Protein_induced_Eosinophilic.10.aspx	
						APRI	F4	0.73	n/a			
						Fibrotest	F4	0.73	n/a			
Flores-Calderon	2012	68	Fatty liver (38), AIH (24), BA (18), idiopathic hepatitis (9), drug toxicity (7), metabolic (3), HCV (2)	9.78 ± 5.36	METAVIR	APRI	F0 vs F3, F4	0.97	0.82	N/A	https://www.medigraphic.com/pdfs/hepato/ah-2012/ah123m.pdf	
						Fibrotest	F0 vs F3, F4	0.9	0.35			
Hukkinen	2016	57	Intestinal failure (TPN ≥ 3 mo)	5.0 (IQR 1.2–10.5)	METAVIR	VCTE	≥F1	0.78	4.25 kPa	1-82 days	https://web-s-ebscohost-com.mclibrary.idm.oclc.org/ehost/pdfviewer/pdfviewer?vid=0&sid=01f51a90-0557-4c8c-a905-39d1573395ab%40redis	TE predicted fibrosis but APRI predicted cholestasis.
						VCTE	≥F2	0.73	4.75 kPa			
						APRI	correlation analysis	no correlation	n/a			
Diaz	2013	48	Intestinal failure	2.0±3.2	METAVIR	APRI	F4	0.67	2	≤ 1 week	https://pubmed.ncbi.nlm.nih.gov/23666459/	
Lebensztejn	2005	63	Chronic hepatitis B	10 (R 4-17)	Batts and Ludwig	APO A-I	3	0.71	1.19 g/L	Same day	https://www.wjgnet.com/1007-9327/full/v11/i45/7192.htm	Only APO A-I helpful for detecting advanced fibrosis.
						HPT	3	0.39	1.01 g/L			
						A2M	3	0.53	1.79 g/L			
Lebensztejn	2007	63	Chronic hepatitis B	10 (R 4-17)	Ishak	YKL-40	Stage > 2	0.387	n/a	Same day	https://pubmed.ncbi.nlm.nih.gov/18217402/	Not helpful
Lebensztejn	2004	48	Chronic hepatitis B	8 (R 4-16)	Batts and Ludwig	HA	Stage > 2	0.84 (combined with HA)	27 ng/mL	Same day	https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.20147	
						Laminin-2	Stage > 2	0.84 (combined with laminin-2)	34.9 ng/mL			
Selimoglu	2004	49	Chronic hepatitis B	9.1 ± 4.1	Knodell index	APO A-I	Portal fibrosis 3, 4	0.41	n/a	N/A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572119/	
McGoogan	2010	36	Chronic viral hepatitis (HBV, HCV)	11.6 (R 1-20)	METAVIR	APRI	F2, F3	0.71	n/a	≤ 4 months	https://pubmed.ncbi.nlm.nih.gov/20118806/	
						APRI	F4	0.52	n/a			
Hong	2019	16	Intestinal failure (TPN ≥ 3 mo)	4.5 (IQR 2.6-8.7)	METAVIR	VCTE	≥F2	0.883	6 kPa	< 1 year	https://pubmed.ncbi.nlm.nih.gov/30879747/	
Alkhouri	2013	67	NAFLD	R 5.5-11.3	METAVIR	VCTE	≥F2	1	8.6 kPa	N/A	https://web-p-ebscohost-com.mclibrary.idm.oclc.org/ehost/pdfviewer/pdfviewer?vid=0&sid=b8fd8127-7e6c-45f6-b1c2-77a25283e0c1%40redis	
						PNFI	≥F2	0.75	8.2			
Lebensztejn	2011	52	NAFLD	12 (R 4-19)	Kleiner	HA	≥F1	0.672	19.1 ng/ml	Same day	http://www.actabp.pl/pdf/4_2011/563.pdf	
						Laminin-2	Mann-Whitney: No fibrosis vs ≥F1	ns	n/a			
						YKL-40	Mann-Whitney: No fibrosis vs ≥F1	ns	n/a			
						Cytokeratin-18 M30	≥F1	0.666	210 u/l			
						HA and Cytokeratin-18 M30	≥F1	0.73	same as above			
Nobili	2008	52	NASH	13.6±2.44	Brunt	VCTE	≥1	0.97	5.1 kPa	≤ 6 months	https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22376	
						VCTE	≥2	0.99	7.4 kPa			
						VCTE	≥3	1	10.2 kPa			
Mandelia	2016	201	NAFLD	10.7 ± 2.5		Cytokeratin-18 M30	≥F1	0.75	n/a		https://pubmed.ncbi.nlm.nih.gov/26835904/	
						Cytokeratin-18 M30	≥F2	0.77	n/a			
						Cytokeratin-18 M30 and waist circumference	≥F1	0.842	82			

Alkhouri	2014	242	NAFLD	12.4 ± 3.1	METAVIR	APRI	F3, F4	0.67	n/a		https://pubmed.ncbi.nlm.nih.gov/25121514/	
						NFS	F3, F4	0.6	n/a			
						FIB-4	F3, F4	0.64	n/a			
						PNFS	F3, F4	0.74	n/a			
El Shabrawi	2010	50	Chronic hepatitis C	10.52 ±4.83	METAVIR	Fibrotest	≥F2	0.97	0.25	N/A	https://pubmed.ncbi.nlm.nih.gov/20110820/	
Nobili	2010	100	NAFLD	N/A	METAVIR	HA	≥F1	0.88	1200 ng/mL	Same day	https://pdf.sciencedirectassets.com/273555/1-s2.0-S1931524410X00093/1-s2.0-S1931524410001015/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEAwaCXVzLWVhc3QtMSJIMEYCIQCjAUzmC2sX3bon7fw9Wyi89gmAJ2WmSlaul1bjHXX3XQlhAKXUtfIHPVKbqNZezLo7skoXkHCQQkvFp2%2Bqox9lhwtDlmKvoDCDUQB8oMMDU5MDAzNTQ2ODY1IgxTAzVUapSGjotMmiLlq1wPfZxy2xHQUUVAcmHfHrpXm3kkgFAEJHacdhAjvksQ4ZRx3ewDxcZLZEBmPX2etwEMxPxj7PLbxDDI5RtgowKvhvZ3gUTS4qgug21gSYMdJqOaH3ibr8iDeKsDS9tglw6mWRDJ3kSalidZgfPSedovRDnA%2FgDhFzHaEzOdSzFrWWnzuxMTq9VdeZCk7%2FbTBc3tHYT4D9GEXPRX9sVju6EeXDGlFj%2F7pN9m77vqoq2yElgfj0fvbX8V9o9EGE9AmDgU0qPJwbiqre9TsoBxIl2qke%2FDGRO9VKHCJPxt2bNzCuWrYka92AvcGTgQjBw8gzrHVBiOgqPS7IZTqQs6vGPN%2Fv3QJbbVy%2BVqOBNzCt6UgQtjnkkJnAcaPRlnzGOz%2f7LTwObJeLMb0ezBmoYn1omRJpXcfhPl4kAob%2FEF8R%2BBthflawIK8GU%2BhZ9Y03HPlRlGQo0h2Ey3dPNgh4omGVcWKNj%2FNIAD3RUdU%2B8Mk90S38XzoKPsue2wAWo2SiaVoAihbdZ6iHsBg5gHw%2FKRJcQ5K8S1lwfHpfSg%2FZCR3ArOQ%2FKhyLBXZqjnMNWNrh%2FcVpOEw%2BHMpstcaspwAlN2%2Fk0M%2FRYZqPfRly7D7kDSDPoaDiS0bnPDEQwwpqsjwY6pAG8dNLUDpxnWPlefQAV5FjxY%2FDNCEXg8ELYHPoBbCOrl9H%2BtEKJFbg64Vp%2B%2F%2FfcyxGA5g1iXy4rGNnMYoNfPf8373lpMmh5823wW%2FHKgzchgoT%2BSMnFNj4P5i6OuS9LUHzY%2BactrIPvUg0zn%2FJb6mmBrdF0HfYvr8zQKJMvcapBYNKYNt%28sjfDdBdkDaxQrNtIQ9IXAaMugCu3HaO%2BZ2OdfbQyvlg%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220121T205015Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRKFE2XMT%2F20220121%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=5fe1dea571edc9e5851e257c7cf51f43f0a609ea1787a96fc856d7d18f161d30&hash=c45d793723ea7adb40587		
Umetsu	2018	28	PSC	9	METAVIR	WFA+ -M2BP	F3, F4	0.9	n/a	N/A	https://pubmed.ncbi.nlm.nih.gov/29168311/	
						APRI	F3, F4	0.85	n/a			
						FIB-4	F3, F4	0.81	n/a			
						AST/ALT	F3, F4	0.802	n/a			
Yang	2012	77	NAFLD	12.2 ± 2.2	METAVIR	FIB-4	F2, F3	0.81	n/a	Same day	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319949/	
						Forns index	F2, F3	0.73	n/a			
						APRI	F2, F3	0.7	n/a			
						NAFLD fibrosis score	F2, F3	0.58	n/a			
						AST/ALT	F2, F3	0.53	n/a			
						PGA	F2, F3	0.45	n/a			
						PNFI	F2, F3	0.41	n/a			
Farmakis	2019	70	NAFLD (47), infectious (23), metabolic (11), AIH (7), PSC (4), BA (4), LT (1), ARPKD (1)	10.9 ± 6	METAVIR	2D-SWE	≥F1	0.89	1.29 m/s	≤ 1 month	https://link-springer-com.mclibrary.idm.oclc.org/content/pdf/10.1007/s00247-019-04493-3.pdf	
					Ishak	2D-SWE	≥1	0.89	1.29 m/s			
Fitzpatrick	2010	45	NAFLD	12.7 (IQR 10.2–14.3)	METAVIR	Cytokeratin-18 M30	≥F2	0.66	200 IU/L		https://pubmed.ncbi.nlm.nih.gov/20808246/	
						Leptin	Mann-Whitney: No fibrosis vs ≥F2	significantly different	F0, F1: 29 ng/mL; ≥F2: 70 ng/mL	≤ 3 months	https://pubmed.ncbi.nlm.nih.gov/20808246/	
						Adiponectin	Mann-Whitney: No fibrosis vs ≥F2	ns	n/a			
						HA	Mann-Whitney: No fibrosis vs ≥F2	ns	n/a			
						HS-CRP	Mann-Whitney: No fibrosis vs ≥F2	ns	n/a			
Hartley	2006	93	Posttransplant (43), rest unknown	7.5 (R 0.07-19)	Ishak	HA	Ishak > 3	0.69	50 ng/mL	≤ 2 days	https://oce-ovid-com.mclibrary.idm.oclc.org/article/00005176-200608000-00014/PDF	
Galina	2021	32	Various CLD: PFIC (22), nonspecific (22), cryptogenic (16), genetic (16), Wilson (9), HCV (6), PV agenesis (6), WT therapy (3)	7.1±4.9	METAVIR	2D-SWE	≥F3	0.98	8.7 kPa	≤ 3 months	https://link-springer-com.mclibrary.idm.oclc.org/content/pdf/10.1007/s00247-020-04959-9.pdf	Two groups: chronic necroinflammatory vs cholestatic. kPa higher with cholestatic
		33	AIH	8.1±4.4	METAVIR	2D-SWE	≥F3	0.98	8.7 kPa			
		19	BA	0.2±0.1	METAVIR	2D-SWE	≥F3	0.98	16 kPa			
Teufel-Schäfer	2021	75	Unknown (25), AIH (19), NASH (13), metabolic (12), Wilson (11), posttransplant (11)	12.3 (R 0.4–21.5)	METAVIR	VCTE	≥F3	0.83	10.6 kPa	≤ 3 months	https://link.springer.com/content/pdf/10.1007/s00431-021-04001-6.pdf	compared different histological grading systems. Chevallier et al. includes all compartments of the liver. All are good
					Desmet	VCTE	≥F3	0.81	10.6 kPa			
					SQS	VCTE	≥F3	0.89	17.6 kPa			
					METAVIR, Desmet, SQS	APRI	Kruskal-Wallis: no fibrosis vs ≥F2	ns	n/a			
Chen	2021	168	BA, before KPE	64.2 ± 20.8 days	METAVIR	2D-SWE	≥F1	0.94	9.1 kPa	N/A	https://kjronline.org/Synapse/Data/PDFData/0068KJR/kjr-22-959.pdf	difference between BA and non-BA cholestasis in infants
							≥F2	0.84	12.1 kPa			
							≥F3	0.92	13.5 kPa			
							≥F4	0.86	15.7 kPa			
		48	Non-BA: neonatal hepatitis (79), PFIC (6), citrin def (6), choledochal cyst (4), Alagille (4)	64.2 ± 20.8 days			≥F1	0.87	9 kPa			
							≥F2	0.9	9 kPa			
							≥F3	1	14.3 kPa			
							≥F4	0.98	14.5 kPa			
						Fibronectin	correlation analysis	significant but weak correlation	n/a			
						HA	correlation analysis	significant but weak correlation	n/a			
						Laminin-2	correlation analysis	no correlation	n/a			
						Procol-3	correlation analysis	no correlation	n/a			
						COL-4	correlation analysis	significant but weak correlation	n/a			
Lee	2021	30	Hepatitis (20), BA (20), NAFLD (17), PFIC (10)	5.1 (R 0-18)	METAVIR	2D-SWE	≥F2	0.95	11.3 kPa	≤ 3 days	https://bmcmedimaging.biomedcentral.com/track/pdf/10.1186/s12880-021-00601-8.pdf	
							≥F3	0.92	18.1 kPa			

Mansoor	2015	92	NAFLD	13.3 ± 3	METAVIR	APRI	≥F1	0.8	n/a	N/A	https://link-springer-com.mclibrary.idm.oclc.org/content/pdf/10.1007/s10620-014-3494-7.pdf	Stratified into adolescents; found APRI and AST/ALT to be helpful in this group.
						AST/ALT	≥F1	0.572	n/a			
						NFS	≥F1	0.477	n/a			
						FIB-4	≥F1	0.547	n/a			
						ALL	≥F2, ≥F3	Lower ROC	n/a			
Ding	2022	51	BA, before KPE	N/A	METAVIR	2D-SWE	F4	0.84	16.1 kPa	N/A	https://pubmed.ncbi.nlm.nih.gov/34850287/	
Zhou	2021	35	BA, post-KPE	N/A	METAVIR	2D-SWE (conventional USG guidance)	correlation analysis	significant (r=0.83)	n/a	N/A	https://pubmed.ncbi.nlm.nih.gov/33966098/	Segmental deformation after KPE may hinder noninvasive evaluation of fibrosis. USG guide 2D-SWE might be helpful.
						APRI	correlation analysis	ns	n/a			
Dhyani	2015	24	NAFLD (20), viral (21), AIH (13), PSC (8), DILI (8), posttransplant (8)	17 (R 1-21)	METAVIR	2D-SWE	≥F2	0.62	8.8 kPa	Same day	https://pubmed.ncbi.nlm.nih.gov/26503488/	highest kPa with cholestatic liver disease group (12.12 kPa)
Akyuz	2021	46	Cholestatic (30), congenital/metabolic (28), AI/inflammatory (15), nonspecific/normal (26)	6.5 ± 5.5	METAVIR	2D-SWE	≥F2	0.953	8.92 kPa			
Kim	2021	165	BA (55), non-BA cholestasis (45)	57.2 ± 36.3 days	METAVIR	APRI	F3, F4	0.72	0.78	≤ 1 month	https://kjronline.org/Synapse/Data/PDFData/0068KJR/kjr-22-253.pdf	
						MRI-Spleen size	F3, F4	0.72	5.9 cm			
						MRI-Liver ADC	F3, F4	0.67	1.044 × 10-3 mm²/s			
						MRI-ADC ratio liver/spleen	F3, F4	0.651	1.22			
Gao	2017	53	BA, before KPE	62.08±29.59 days	Batts and Ludwig	ARFI	≥F2	0.823	1.53 m/s	≤ 3 days	https://pubmed.ncbi.nlm.nih.gov/28407283/	
							≥F3	0.884	1.80 m/s			
							F4	0.919	2.16 m/s			
Tutar	2014	76	NASH (17), storage (14), AIH (12), Wilson (9), cryptogenic (9), CFLD (5), viral (5), CHF (4), PSC (2)	7.7 ± 5.5	Brunt	2D-SWE	≥F1	0.952	10.6 kPa	Same day	https://oce-ovid-com.mclibrary.idm.oclc.org/article/00005176-201406000-00018/PDF	Higher mean SWE in NASH group.
Alhashmi	2020	46	AIH (22), NASH (20), posttransplant (17), PSC (7), PFIC (4), TPN (4), Fontan (4), BA (4)	11.5 (IQR 8.0-14.3)	METAVIR	2D-SWE	≥F2	0.75	1.89 m/s	≤ 6 months	https://pubmed.ncbi.nlm.nih.gov/32588095/	AUROC increased to 0.86 in the subgroup without steatosis.
Lee	2020	155	BA (71), non-BA cholestatic (29)	57.6 ± 34.4 days	METAVIR	MRI-periportal thickening	≥F2	0.9	4.2 mm	≤ 1 month	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284183/	
						MRI-spleen ratio	≥F2	0.741	0.85			
						APRI	≥F2	0.712	0.44			
Mo	2021	35	BA, before and after KPE	644±1203 days	METAVIR	Age at MRI	F4	0.91	132 days	N/A	https://link-springer-com.mclibrary.idm.oclc.org/content/pdf/10.1007/s00247-020-04823-w.pdf	
						APRI	F4	0.86	1.3			
						BSA-adLLV	F4	0.83	855			
						Combined index (APRI, adLLV, age at MRI)	F4	0.94	0.689			
Ueno	2021	35	BA, after KPE	10.6 (R 1–39)	METAVIR	Autotaxin	≥F3	0.93	1.64 mg/mL	N/A	https://pdf.sciencedirectassets.com/272462/1-s2.0-S0022346821X00061/1-s2.0-S0022346821002682/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEGYaCXVzLWVhc3QtMSJHMEUCIQDNXnuaqPwHYbXB8O5vxhB2VTUernQ8v6XTNQpRJzxkWgIgNIIqxhVctiJF8O0VNpcdHMafOAO3eDG1M7GcqnXFiIEqgwQIj%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAEGgwwNTkwMDM1NDY4NjUiDLeLM0L2vBI6jDP%2B6SrXA57ZMJ3XPGyi1ulFOIRPSQVR%2FuUHFzGlnsa5xKEpOE1jLYqiO9vOrsx53nsk6D%2Bf8IQQ0z3wcpwqLli3KPXIKXwmybKy264bvVHQdctB5106YKUiX74IK21DFXvqKL%2F6sNPYNJFV6nzPk1xb7DvEjPrtZwmnSORmsKKTDXAXEhpI4USzMRUAFXAvPcIFU2I5a61c8LtkyzOQGcD9QJX17EYQaZZAIMwUpPE4oeluvaEPIDHzF0eJ%2F3rB2gYG9Jct1GTZfgP8SOZYsI50JjerX0411PgGNbgVM42ERCKLn%2FXJvfCR6eJO2kuOqDD9MS8ZuhXpITvOURIGy2I30wswy%2BBmrJ9FUxxYu0xgKex43w04QmhUKC7Qtodp575ETYy6H6cNnQ8jmk%2FJkjoZUh%2Fnb90nb9cYsif2AHzQ8mLgNX7HBr6mGA9MUoNaNYfNozbycH8Mczh1PHq0PDrB5aJMW%2BC0i5mQ%2F%2FqKHhAfdkWZDv1oRIa23J1q2pLnw69w7NOlcNqWQ7hE7zOnQGxSavkfiOOR%2B2n2YeTb%2FTpeuY66p3m4MpsEr9q%2FrcqZlXE4I4wJtfM8f%2FLTl0CuV0D0yI%2F8gAWGB%2FuXn3mj5vChRGO%2FqZ3vAIROsdhrHTDA%2FL%2BPBjqlAbpm7hTivOTLCoqMu9mJKcjfkOD%2F3mK%2BgxPjLwqxxROESns81IZIjK%2BODtKSbxqD2gb6FEMK1wlxO9Cqj80uJE%2FCOQZ6M3LQIAm6HKMrpvgKXgTxTuoPcjgNzkmToyWYcH8iiOpf%2BCikqqKQBJEmP%2BjZrMtH8DyMcLf4BcWZsI9mbpX4dSTspWln1MRmHAJGrS0IfA2VCQRKbdbvK8CYbTQAfdCveQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220125T143721Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRSX6FYNZ%2F20220125%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=c6fc92fb5858d6f5e2a21672b2d666f687b069946	
						M2BPGi	≥F3	0.95	1.29 COI			
						AST/ALT	≥F3	0.59	1.1			
						FIB-4	≥F3	0.43	2.5			
						COL-4	≥F3	0.79	6.9 mg/L			
Shen	2015	31	BA, before KPE	75.58 ± 21.84 days	METAVIR	VCTE	F4	0.87	15.2 kPa	N/A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462734/	
						APRI	F4	0.54	1.86			
Kim	2010	35	BA, before KPE	2.36 ± 1.46 months	METAVIR	APRI	≥F3	0.92	1.01	Same day	https://oce-ovid-com.mclibrary.idm.oclc.org/article/00005176-201008000-00016/PDF	
							F4	0.91	1.78			
Yamada	2017	64	BA, before LDLT	1.1 (R 0.4-16.0)	METAVIR	M2BPGi	F4	0.92	n/a	N/A	https://pubmed.ncbi.nlm.nih.gov/27349650/	
Umdomsinprasert	2021	96	BA, after KPE	10.00±6.17	METAVIR	Circulating COMP; COMP mRNA in the liver	T-test: F0 vs ≥F1	significantly different	higher in fibrotic liver	Same time	https://www.nature.com/articles/s41598-021-95805-x.pdf	
Shiau	2020	40	Alagille		METAVIR	APRI	≥F3	0.72	2.97	≤ 3 months	https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep4.1569	
						FIB-4	≥F3	0.68	n/a			
		24	PFIC		METAVIR	APRI	≥F3	0.74	0.99			
						FIB-4	≥F3	0.65	n/a			
Pokorska-Śpiewak	2017	30	Chronic hepatitis C	9.4 ± 3.7	METAVIR	APRI	≥F2	0.75	0.67	N/A	https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-017-2462-1.pdf	Normalized for BMI
						M-APRI	≥F2	0.84	0.58			
						FIB-4	≥F2	0.71	0.18			
						M-FIB-4	≥F2	0.82	0.179			
						B-AST	≥F2	0.85	92.82			

Behairy	2016	90	HCV (56), AIH (22), Wilson (22)	N/A	Ishak	VCTE	≥1	0.81	4.75 kPa	N/A	https://www.wjgnet.com/1007-9327/full/v22/i16/4238.htm#B2	Similar AUROC of VCTE across etiology groups.
							≥2	0.95	6.65 kPa			
							≥3	0.96	8.25 kPa			
							≥4	0.99	13.0 kPa			
							≥5	0.99	18.0 kPa			
							6	0.94	29.5 kPa			
Behairy	2014	33	HCV	10.95 ± 4.53	Ishak	ITIH-4	correlation analysis	significant but weak correlation	n/a	N/A	https://pubmed.ncbi.nlm.nih.gov/25295185/	
						APRI	correlation analysis	no correlation	n/a			
						FIB-4	correlation analysis	no correlation	n/a			
Hamidieh	2014	83	Thalassemia major	8	METAVIR	VCTE	n/a	0.73	3.2 kPa	N/A	https://www.astctjournal.org/article/S1083-8791(14)00474-1/pdf	
						FIB-4	n/a	0.61	0.699			
						VCTE-FIB-4	n/a	0.74	3			
Shah	2018	48	Neonatal cholestasis (non-BA)	3.5 ± 2.8 months	METAVIR	APRI	F4	0.746	1.38	Same day	https://pdf.sciencedirectassets.com/321204/1-s2.0-S1665268118X70045/1-s2.0-S1665268119304824X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEG8aCXVzLWVhc3QtMSJGMEQCIA0wm6XPFyUXR%2F9FkIgNoq8XBRngH8tVZg2exGj8ZQCBAiBhzz45R%2Br7mimWm3hY0zo3z%2F%2FNRbYNiMIKIh1DyH%2FBiSqDBAiY%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAQaDDA1OTAwMzU0Njg2NSIMdDxA4hbRAKr%2B9glhKtcDy26G0jGcsABhKP3kqVq3K08PrdizrBZuG71sZr80%2FEyxa5OIfvHb3dLILKeu%2BXezwK2Ua8vzMBlfcyXXuiKRuUN89HEQYjSwnMdCkI3QcGrsDdGUbae0dD0XqjHkb%2BW2Vfa2q5L%2Fv6b3LiaHwI1d1V2fZh8PNVak5%2FbFp6ltAzx1beiDAgxrjbHfIMbMYTTCRnNahvRkawo6Udib8Q6IPYy0NIAwXA3gZJGmR2alzooOPqgQhED5yCAUxo9ww1sPyhbagXjK7UI26wK6AbBogX9NEiWfqzUewyhytXBDHAIhtnZKcXliRgS%2B6MOy4ACUfiB7ivkjVuDSKzQdQZkZVTrrJW6KBAGukWWjc5kfmDRGnd%2BPloXvGm7YXzj3TLHQMjgJtVU%2Foi3bvsBTPYyJXH7D1JwRgPfLxEM%2FFxj7on290DIAj7ZYY%2Fjoxpxpl4NO97LIDZPb03%2BGwIAu29p40XGkkgl0TiY%2Bbd87J5g%2BIOjIneW0vIuzjXIYHHo0Q81eEaVC7ykB8Au1V%2Bb%2FMtb%2FTdhnQVVsjJrXzBV6QbimFomIF5GbepsarzQxM3c07HRYUrNIKbbZBjuq2mgqUzwm4CRm8ce9TfAgRGQUi14WsRQ6bpVzXJMLH7wY8GOqYBNo%2BLWK1n0z9Ns6vDEe1qmUHeJeKeB%2FILtMgnyjXCGF22OytY%2Fb8cCoWELaGk1r3y%2FxYtZ%2F6EAAkc69q9tWALEvjlKoCAdHfo%2F2tZ%2BYvOJoy8KVM%2BYMTcXFrXI13Wlhz6L%2B3%2FIsr840T8zGlLUbCVBqtky3F1Kg8%2BWwx4jAqtgSUy2Iz2oy8MOlZUAR3Y%2FQfEOoZxrwjG5br3Tkzc80uQf2TMVprA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220125T230324Z&X-Amz-SignedHeaders=host&X-Amz-Expires=299&X-Amz-Credential=ASIAQ3PHCVTYZSK6XPLM%2F20220125%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=61ad80646125ef1e1d5315126c8870debe42a122	
Hudert	2018	67	NAFLD	14.1 ± 2.2	5 stages	Time-harmonic elastrography	≥ stage 1	0.88	1.52 m/s	Same day	https://pubs.rsna.org/doi/pdf/10.1148/radiol.2018172928	Successful detection of liver fibrosis in obese children
							≥ stage 2	0.99	1.62 m/s			
							≥ stage 3	0.88	1.64 m/s			
Garcovich	2017	68	NAFLD	12.6 ± 2.48	Brunt	2D-SWE	≥F1	0.92	5.1 kPa	N/A	https://pubmed.ncbi.nlm.nih.gov/27982761/	Average BMI 28
							≥F2	0.97	6.7 kPa			
Ozkan	2017	75	AIH, BA, Wilson, a1AT, viral	5.7 (R 2–12)	Knodell	pSWE - VTQ	≥F3	0.83	2.09 m/s	Same day	https://onlinelibrary-wiley-com.mclibrary.idm.oclc.org/doi/pdfdirect/10.1002/jum.14277	VTQ and VTIQ
						pSWE - VTIQ	≥F3	0.85	2.17 m/s			
Dillman	2015	62	Posttransplant (18), nonspecific (16), normal (15), BA (13), AIH (8), PSC (8)	8.0±5.8	Ishak	pSWE - VTQ	≥F3	0.84	2.07 m/s	Same day	https://link-springer-com.mclibrary.idm.oclc.org/content/pdf/10.1007/s00247-015-3345-5.pdf	
						pSWE - VTIQ	≥F3	0.86	2.15 m/s			
Franchi-Abella	2016	45	Posttransplant (40), BA (24), cholestasis (18), other (18)	2 (R 0.08-17)	METAVIR	2D-SWE-SL15-4	≥F2	0.99	9.50 kPa	Median 2 days	https://pubs-rsna-org.mclibrary.idm.oclc.org/doi/pdf/10.1148%2Fradiol.2015142815	
							≥F3	0.96	32.8 kPa			
						2D-SWE-SC6-1	≥F2	0.97	12.1 kPa			
							≥F3	0.98	n/a			
Dardanelli	2020	213	Posttransplant (43), BA (16), AIH (12)	6.9 (R 0.2 - 18.4)	Knodell-Ishak	2D-SWE	Stage ≥ 3	0.91	12 kPa	≤ 2 months	https://pubmed.ncbi.nlm.nih.gov/32072246/	Hemosiderosis may be a confounder in 2D-SWE.
							Stage ≥ 5	0.95	18.5 kPa			
Shin	2014	47	BA, before KPE	60 (9.5-179 days)	METAVIR	VCTE	≥F3	0.86	9.8 kPa	N/A	https://pubmed.ncbi.nlm.nih.gov/24764341/	S probe success rate significantly higher than M probe.
							F4	0.96	18.1 kPa			
Hukkinen	2019	58	BA, after KPE	8.3 (R 2.5-10.8)	METAVIR	VCTE	F4	0.82	23.8 kPa	Same day	https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep4.1306	For post-KPE follow up. Highest accuracy in oldest tertile (median 10.8 years)
Tomita	2015	92	BA, age ≤ 1 year and before KPE	73 (R 27–195 days)	METAVIR	iBALF (TB, platelet, age)	≥F2	0.86	3.56			
							≥F3	0.9	4.34			
							F4	0.89	5.12			
						APRI	≥F2	0.88	n/a			
							≥F3	0.84	n/a			
							F4	0.83	n/a			
Yang	2015	91	BA, before KPE	73 ± 23 days	METAVIR	APRI	≥F3	0.75	0.95	≤ 1 week	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438023/	
							F4	0.81	1.66			
Grieve	2013	260	BA, before KPE	58 (R 14-209) days	Macroscopy	APRI	Macroscopic cirrhosis	0.83	1.22	Same day	https://pubmed.ncbi.nlm.nih.gov/23583135/	
Chen	2016	24	BA, after KPE		METAVIR	SSWE	≥F2	0.79	9.4 kPa	≤ 1 week	https://www.nature.com/articles/srep31057.pdf	
						APRI	≥F2	0.65	0.7			
						SSWE + APRI	≥F2	0.78	n/a			
						SSWE	≥F3	0.81	10.8 kPa			
						APRI	≥F3	0.64	0.93			
						SSWE + APRI	≥F3	0.76	n/a			
Rumbo	2017	36	Intestinal failure (TPN ≥ 3 mo)	2.02 (IQR 0.82–5.65)	METAVIR	APRI	≥F3	0.79	1.6	≤ 2 weeks	https://pubmed.ncbi.nlm.nih.gov/26826264/	
Wang	2020	137	Infantile cholestasis: BA (66%), choledochal cyst (26), CMV hepatitis (3)	54.0 (42.0–67.0) days	METAVIR	Procol-3	≥F1	0.843	242.3 ng/mL	N/A	https://pubmed.ncbi.nlm.nih.gov/32296668/	
							≥F2	0.789	n/a			
							≥F3	0.82	n/a			
							F4	0.891	698.7 ng/mL			

Mosca	2019	204	NAFLD	R 5-17	5 stages	Procol-3	≥F2	0.92	8.89 ng/mL	N/A	https://web-p-ebscohost-com.mclibrary.idm.oclc.org/ehost/pdfviewer/pdfviewer?vid=0&sid=6eb98632-f569-4497-85bd-acd0cb87bfb%40redis	
							≥F3	0.99	13.2 ng/mL			
						APRI	≥F2	0.77	n/a			
							≥F3	0.85	n/a			
						FIB-4	≥F2	0.74	n/a			
							≥F3	0.77	n/a			
Peng	2015	32	BA, before KPE	461 (11-4616) days	METAVIR	MRI-right LTPAR	F4	0.88	0.84	≤ 2 months	https://link-springer-com.mclibrary.idm.oclc.org/content/pdf/10.1007/s00330-015-3716-1.pdf	
Hanquinet	2013	39	LT (59), BA (8), CHF (8), Alagille (8), Caroli (6), PFIC (6)	5.6 (R 0-14)	METAVIR	pSWE	≥F1	Sens: 0.82, Sp: 0.45	1.34 m/s	≤ 3 months	https://pubmed.ncbi.nlm.nih.gov/23271404/#:~:text=Conclusion%3A%20Acoustic%20radiation%20force%20impulse,the%20time%20of%20liver%20biopsy.	
							≥F2	Sens: 1.0, Sp:n/a	2 m/s			
Trout	2018	86	NAFLD (56), PSC (15), BA (4), PFIC (4), unspecified (4)	14.2 (R 0.3-20.6)	Ludwig	MR elastography	Ludwig ≥ 2 (no steatosis)	0.82	2.49 kPa	≤ 3 months	https://pubs.rsna.org/doi/pdf/10.1148/radiol.2018172099	
							Ludwig ≥ 2 (with steatosis)	0.53	2.28 kPa			
Xanthakos	2013	35	NAFLD (77), PFIC (3), Wilson (3), A1AT (3), PSC (3), T1DM (3), transfusion (3)	13 (IQR 12-16)	5 stages	MR elastography	Stage ≥ 2	0.92	2.71 kPa	N/A	https://www.jpeds.com/article/S0022-3476%2813%2900963-3/fulltext	
Raizner	2017	154			METAVIR						https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316380/	
Lam	2020	54	AIH, ASC, PSC	16							https://pubmed.ncbi.nlm.nih.gov/33163837/	
Phelps	2016	41	Posttransplant (63)		METAVIR	pSWE	≥F1	PPV = 100%; NPV = 24%	1.7 m/s	Same day	https://pdf.sciencedirectassets.com/271157/1-s2.0-S0899707116X00022/1-s2.0-S0899707116301528/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIF3ygEAKBkDa1vouhdtHTFpllx%2FgoxpljOKEEeU4zSirAiEA7WiPwFYdbRWJ%2FUyH5I75jNw%2F3BoZgO5bNyZWlw5ffCcq%2BgMINBAEGgwwNTkwMDM1NDY4NjUiDB68WzJMYjuU%2F%2FdLeyrXA4Fj33J1gx1bwwUI%2BJmdRXrgLXKM4dmvYvarrXvWKaQ2Ia9cIzxiRg%2BEe6PhAPMqNL0SVIEjL6qiigUet2Gk9OLNhidMrC%2BTFij2n8SPOI80wE%2FIL0QJSVeepDDOEsdy82s9g8YJm3PaSpBNOs1ZEDd8XR3JrJDnTd7zbUWRy9TshP1ZC7fV0ztcTxYZjGfDH7dQx%2BAPMM5XcGmXWz99lCpDOGI7mGTRC7bb6rwNFDskMDjFsq0%2FDRDwjKITTEkupr3QgbeWF4wX%2FTfO4716zX4QU16WTZKyw03PIN2yYo06uktTfp4%2FvV3V4BZi7Wvfs2ETMSQndIT%2BHy6dSUTCjNTp3WcB4MTw6oQ6RXerW7XTajiTGs8LKsMiUERhKiaW%2BSafuDm35R189Sa87TavbcRPiwcIwTIJGY8ZzQGHs8eAKu0ZGz0v9sCuuuVPEHsTgCBsKnTUBfcFruK5DDnnfeMxDKnB%2Bmb3Q1Z8HfQZW1ww%2BSytUZGvKDRnLL1oqyH2fzx8XVrFiqqTb2A7bITyF1owCpzf%2BtD1i0GOrWgUwWc4YZ4B6QkZZCkjGKZiAohBkYl7ZMiVapdCiDJ8nCMh22ecSMTnZ5w3APDf5kDHoWcRn%2Br6WG5HTCP0uCP8jqIAaHOJqKC4I1YkQnjdG%2BhfzZ18DaPCt2IzyHzkwsjyD1EcINOaUJtqPNem5Wb5iyCvqgRfG%2BNWyczd%2FRZo5P44H%2FCx%2BRjIiTbnnF6mpcQrN%2Fe%2B9w6v02y3zZyy907r%2BdwsffYnQ1d%2FxFdeLfYlwFmjwhpUpgdwzqqXxa6rOddwA40DBMqsAa6JYgu15M15wdKROMBQn8B%2BtBLs2qfgeWqHI3yaoZiA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220131T195846Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRSD6QYNF%2F20220131%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=cfa4f9c8068a1e6b0f74339d79d02ac37706dfab8	
Noruegas	2012	32	Posttransplant (69), CLD (31)	8 (R 1-16)	Batts and Ludwig	pSWE	≥F1	0.834	1.31 m/s			
							≥F2	0.818	1.39 m/s			
							F4	0.983	2.25 m/s		https://pubmed.ncbi.nlm.nih.gov/22002843/	
Schwimmer	2017	90	NAFLD	13.1 ± 2.4	5 stages	MR elastography	≥F1	0.77	2.78 kPa	≤ 6 months	https://pubmed.ncbi.nlm.nih.gov/28493388/	
							≥F3	0.93	3.33 kPa			
Nobili	2009	203	NAFLD	R 3.3-18	NASH CRN	PNFI	Fibrosis	0.85	9	N/A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684116/	
Alkhouri	2011	111	NAFLD	10.5 (IQR 9.5-11.4)	NASH CRN	PNFI	≥F1	0.761	3.47	N/A		
						ELF	≥F1	0.924	n/a			
						PNFI + ELF	≥F1	0.944	n/a			
						PNFI	F3	0.618	8.99			
						ELF	F3	0.962	8.49			
Hermeziu	2009	16	HCV	10.4 ± 1.0	METAVIR	Fibrotest	≥F2	0.62	0.48		https://pdf.sciencedirectassets.com/276860/1-s2.0-S0399832010X00021/1-s2.0-S0399832009002619/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEEMaCXVzLWVhc3QtMSJGMEQCIHJylqqDSRq%2Fr5BcWg0Ied8uq%2Bey8DuGFVyHzfSeo9EqAiBi993FHHXJEHzjtIFE4ZvjLYL91pQEgk22h1fOEQLrvyr6Awh8EAQaDDA1OTAwMzU0Njg2NSIMl9vgLmjOy2OSIX9IKtcDzhs8M0ajIEymFjqhgPR%2BDn3wF97d2c3yCTMIMIIDDuvdbF51UwA1OFWlz9uberjMfZ%2BOXF%2Ftxi0ec9RxR8EZvBQmAplg8g9kjOtGkV7p6NMGUuF1ysO5oz1MEzxQyafO%2B7N6DcnAkLxyogPHpI0EZ8ZJvPHBSA0s28Q5LJFvx0NEH8V0SzD06Oej6CGzAtPCYDN03m8ZFU4mdbBDR%2BQb01DXFZRELBQKI5x1KwnseHeCPc1uXrOOiyc%2B2Wrw1iUNss2u7s1Ffd3xsI5DKf4iuonJOEQJbYEf72nR%2Fr6xg4Nd1ekkY5HDbjux3X4DxaxbRu9Ivm3b3e3C6LIQAoScnU5Ro0eJ7Of9mIidMOvPRiw1lKWQi1blu7WzTMAKcR3GN%2FL7%2BHIezJ2jceqNT8C6kqW3L0Dmx%2FKNcLo9YOPen1kT3IqTLWQDBy8%2Bl04Rbgjc%2B6FEuvaGLOs31ZQd%2FoO%2Fysis/%2BllwRw2KkyOyaW%2B15Ndpf9DKrdTS1eZazUSlmmiA6dQ%2FDE8h2ITCkI9SCu55LYsXDKJvTsrWty0svZEa0l676cB2vAUZrGVE1iQ7hWM00KvN8w7hsAlsF0INRjv9GyiQ8FYg95B5HTSNFWAYPwi5VZWAqXQuMNO%2B8I8GOqYBXnWfQ2jAh9FFvS8tpSMo33L4U5auLryWlla1Dwfj8NP0tTSJg4fUP2SSV4ONAolo1HN5CiEwd1R7Jg1fr%2FOZfa2orHFhrFvEyw%2FRQQ3kzoWt2o2cAo236KSt4MSE3RF9vqFGZLOpxABBMnF7bWGVHgkPUD%2FEG0WAq2cCzXREtq3UrY29YOJnRcZ1ykCQOVxO05OQwDi6rvg9pIBEQm8w9ZRGfZ5aOQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20220203T201357Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYWXFTBFDL%2F20220203%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=46556e3da72240197b180011337ffd69cea90d0bfb507067076af8a845a67e4d&hash=c9708a427f9d98b9f7e4	
							≥F3	0.72	n/a	< 8 months		
							F4	0.84	n/a			
Valva	2013	22	HCV	8 (R 1-17)	METAVIR	sFas	≥F2	0.719	6815.14 pg/mL	N/A	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0053519&type=printable	
						sFas	≥F3	0.812	7416.56 pg/mL			
						Caspase activity	≥F2	0.656	1490 RLU			
Nobili	2009	112	NAFLD	13.8±3.3	Brunt	ELF	≥stage 1	0.92	9.28	≤1 week	https://pubmed.ncbi.nlm.nih.gov/18992746/	
							≥stage 2	0.98	10.18			
							≥stage 3	0.99	10.51			
Xu	2021	157	Chronic hepatitis B	3.0 (IQR 1.9, 4.1)	METAVIR	VCTE	≥F2	0.732	5.6 kPa		https://pubmed.ncbi.nlm.nih.gov/34240319/	
							≥F3	0.941	6.9 kPa			